Safety Study of JST-018 Immune Treatment in Healthy Adults
This is a first-in-human safety study testing a new experimental immune therapy called JST-018. Researchers want to see how safe it is, how well your body tolerates it, and how your body processes it when given as an injection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 55 years old and in good overall health
- Have a healthy weight (BMI between 18 and 32)
- Not be pregnant, breastfeeding, or planning pregnancy for at least 12 months
- Have adequate muscle tissue in upper arms and thighs for injections
- Not have had recent vaccines (within 30 days) or plans for vaccines during the study
- Not be taking immunosuppressive medications, blood thinners, or heart rhythm drugs
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new injectable drug (VH4011499) for safety and how the body processes it. It's for healthy adults without HIV, and participants will get either the study drug or a placebo (an inactive shot).
This trial tests a new drug called JANX011 in healthy adults to see if it is safe and well tolerated. It is a first step before testing in patients.
This study tests an experimental drug called JL18008 in people with HIV who have been on stable HIV medications for years but whose immune systems (CD4 cells) haven't recovered as expected. The drug may help boost immune function in these patients.
This early-stage trial tests a new medicine called JMT206 in healthy people to see if it is safe and how the body handles it. Healthy volunteers, ages 18 to 60, are needed to help researchers learn about the drug's effects and how it moves through the body.
This trial is testing a new investigational drug called JH013 in healthy volunteers. It’s a first-in-human study to see how the drug is processed by the body and to check for safety.
This trial tests a new drug called JL18008 (a man-made form of Interleukin-7) to see if it can help increase CD4 immune cells in people with HIV who are on effective antiretroviral therapy but have persistently low CD4 counts (between 100 and 350). It aims to improve immune function.
Hear when a new Antiviral Drug trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.